Submissions from 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study., Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan, Elena Garralda, Luis G Paz-Ares, Byoung Chul Cho, Shirish M Gadgeel, Michael Thomas, Stephen V Liu, Matthew H Taylor, Aaron S Mansfield, Viola W Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D Turner, and Vivek Subbiah
SGNTGT-001: A phase 1 study of SEA‑TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress)., Elenda Garralda, Rachel E Sanborn, and See list of authors in comments
The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy., Nikesha Gilmore, Supriya Mohile, Lianlian Lei, Eva Culakova, Mostafa Mohamed, Allison Magnuson, Kah Poh Loh, Ronald Maggiore, Elizabeth Belcher, Alison Conlin, Lora Weiselberg, Mary Ontko, and Michelle Janelsins
Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting., John E Godwin, Bassam I. Mattar, and See list of authors in comments
Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL), John E Godwin and See full list of authors in comments
Assessing the risk of thromboembolism in cancer patients receiving immunotherapy., Abhishek Goel, Arjun Khorana, Thomas Kartika, Sonia Gowda, Derrick L Tao, Rajat Thawani, and Joseph J Shatzel
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature., Jason D Goldman, George Diaz, and Walter Urba
The Dynamics of pre-existing T cells in tumors and the effects of radiation therapy, M Gough
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer., Andrew J Gunderson, Venkatesh Rajamanickam, Cynthia Bui, Brady Bernard, Joanna Pucilowska, Carmen Ballesteros-Merino, Mark Schmidt, Kayla McCarty, Michaela Philips, Brian D. Piening, Christopher Dubay, Terry R Medler, Phillipa Newell, Paul D Hansen, Eric Tran, Ephraim Tang, Carlo Bifulco, Marka R Crittenden, Michael J. Gough, and Kristina H Young
LB180 - Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation, Kevin J. Harrington, Francesca Aroldi, Joseph J. Sacco, Mohammed M. Milhem, Brendan Curti, Ari M. Vanderwalde, Scott Baum, Adel Samson, Anna C. Pavlick, Jason A. Chesney, Jiaxin Niu, Terence D. Rhodes, Tawnya L. Bowles, Robert Conry, Anna Olsson-Brown, Douglas E. Laux, Pablo Nenclares, Lavita Menezes, Alex Deterding, Victoria Roulstone, Joan Kyula, Suzanne Thomas, Praveen K. Bommareddy, Selda Samakoglu, Andrea Pirzkall, Robert S. Coffin, and Mark R. Middleton
First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers., Alan L. Ho, Marshall R. Posner, and Rom Leidner
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors., David S Hong, Olivier Rixe, Vi K Chiu, Patrick M Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N Atkins, Agron Collaku, Floyd E Fox, Margaret A Marshall, and Anthony J Olszanski
Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101., Antonio Jimeno, Joaquina C. Baranda, Matthew H Taylor, and See all authors in comments
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies., Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark Stroh, Alison L Hannah, Song Wang, Henry Castro, and Alexander Spira
Treatment dependent improvements in survival of stage 2/3 rectal cancer patients treated with trimodality therapy between 2006-2016, an NCDB analysis., Hagen F Kennecke, Henry T. Bahnson, and See list of authors in comments
CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial., Hagen F Kennecke, Carl J. Brown, and See full list of authors in comments
Noninvasive biomarkers for prediction and diagnosis of heart transplantation rejection., Yeraz Khachatoorian, Vahe Khachadourian, Eleanor Chang, Erick R Sernas, Elaine F Reed, Mario Deng, Brian D. Piening, Alexandre C Pereira, Brendan Keating, and Martin Cadeiras
"Custom" Plate in a Day-Accurate Predictive Hole Fabrication Using Point-of-Care 3-Dimensional Printing., Baber Khatib, Marcus Couey, Ashish Patel, Allen C Cheng, and Richard Bryan Bell
Updates in Management of Craniomaxillofacial Gunshot Wounds and Reconstruction of the Mandible., Baber Khatib, Savannah Gelesko, Melissa Amundson, Allen Cheng, Ashish Patel, Tuan Bui, Eric J Dierks, and R Bryan Bell
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy., Isaac Kim, Venkatesh Rajamanickam, Brady Bernard, Brie Chun, Yaping Wu, Maritza Martel, Zhaoyu Sun, William L Redmond, Katherine Sanchez, Reva Basho, Heather McArthur, and David B Page
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab., Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan Curti, Walter Urba, Brian D. Piening, and William L. Redmond
Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study., Matthew H Kulke, Hagen F Kennecke, Kris Murali, and Vijay N Joish
Unaltered IL-2 encapsulated in acoustically active lipid microspheres for systemic but targeted microdose delivery to tumor microenvironment., Clayton Larsen, Llew Keltner, William L. Redmond, and Rhodemann Li
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study., Chung-Han Lee, Amishi Yogesh Shah, Drew Rasco, Arpit Rao, Matthew H Taylor, Christopher Di Simone, James J Hsieh, Alvaro Pinto, David R Shaffer, Regina Girones Sarrio, Allen Lee Cohn, Nicholas J Vogelzang, Mehmet Asim Bilen, Sara Gunnestad Ribe, Musaberk Goksel, Øyvind Krohn Tennøe, Donald Richards, Randy F Sweis, Jay Courtright, Daniel Heinrich, Sharad Jain, Jane Wu, Emmett V Schmidt, Rodolfo F Perini, Peter Kubiak, Chinyere E Okpara, Alan D Smith, and Robert J Motzer
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma., Rom Leidner, Marka Crittenden, Kristina Young, Hong Xiao, Yaping Wu, Marcus A Couey, Ashish A Patel, Allen C Cheng, Amber L Watters, Carlo Bifulco, George Morris, Lessli Rushforth, Shorin Nemeth, Walter J Urba, Michael Gough, and R Bryan Bell
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates., John B Liao, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Doreen M Higgins, Jennifer S Childs, Hania N Shakalia, Ron E Swensen, Sasha E Stanton, Anna V Tinker, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Mary L Disis, and Barbara A Goff
Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis., Hongjun Li, Zejun Wang, Zhaowei Chen, Tianyuan Ci, Guojun Chen, Di Wen, Ruoxin Li, Jinqiang Wang, Huan Meng, R Bryan Bell, Zhifeng Gu, Gianpietro Dotti, and Zhen Gu
Effects of yoga, cognitive behavioral therapy, and a behavioral placebo on sleep: A nationwide multicenter phase III RCT in cancer survivors., Po-Ju Lin, Charles E. Heckler, Alison Conlin, and See full list of authors in comments
Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen., Siyu Liu, Emily Bellile, Ariane Nguyen, Katie Zarins, Nisha D'Silva, Laura Rozek, Gregory T Wolf, Maureen A Sartor, INSPIRE Trial Clinical Investigators, and Richard Bryan Bell
Caregiver-Oncologist Prognostic Concordance, Caregiver Mastery, and Caregiver Psychological Health and Quality of Life., Kah Poh Loh, Mostafa R Mohamed, Sindhuja Kadambi, Eva Culakova, Huiwen Xu, Allison Magnuson, Marie Flannery, Paul R Duberstein, Ronald M Epstein, Colin McHugh, Ryan D Nipp, Kelly M Trevino, Chandrika Sanapala, Bianca A Hall, Beverly Canin, Arlene A Gayle, Alison Conlin, James Bearden, and Supriya G Mohile
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!, Michele Maio, Christian Blank, Andrea Necchi, Anna Maria Di Giacomo, Ramy Ibrahim, Michael Lahn, Bernard A Fox, R Bryan Bell, Giampaolo Tortora, and Alexander M M Eggermont
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation., Michele Maio, Michael Lahn, Anna Maria Di Giacomo, Alessia Covre, Luana Calabrò, Ramy Ibrahim, Bernard Fox, and Siena Think Tank
354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study, Vicky Makker, Matthew H Taylor, and See full list of authors in comments
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE., E P Mamounas, M Untch, M S Mano, C-S Huang, C E Geyer, G von Minckwitz, N Wolmark, X Pivot, S Kuemmel, M P DiGiovanna, B Kaufman, G Kunz, A K Conlin, J C Alcedo, T Kuehn, I Wapnir, A Fontana, J Hackmann, J Polikoff, M Saghatchian, A Brufsky, Y Yang, M Zimovjanova, T Boulet, H Liu, D Tesarowski, L H Lam, C Song, M Smitt, and S Loibl
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors., Aaron S Mansfield, David S Hong, Christine L Hann, Anna F Farago, Himisha Beltran, Saiama N Waqar, Andrew E Hendifar, Lowell B Anthony, Matthew H Taylor, Alan H Bryce, Scott T Tagawa, Karl Lewis, Jiaxin Niu, Christine H Chung, James M Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, and Rahul Aggarwal
Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer., Sebastian Marwitz, Carmen Ballesteros-Merino, Shawn M. Jensen, Martin Reck, Christian Kugler, Sven Perner, Daniel Drömann, Torsten Goldmann, and Bernard A Fox
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report., Altaf Mohammed, Roderick H Dashwood, Sally Dickinson, Mary L Disis, Elizabeth M Jaffee, Bryon D Johnson, Samir N Khleif, Michael N Pollak, Jeffrey Schlom, Robert H Shoemaker, Sasha Stanton, Georg T Wondrak, Ming You, Hao Zhu, and Mark Steven Miller
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)., Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Mäenpää, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michalis Liontos, Michael A Gold, Yolanda Garcia, Sudarshan K Sharma, Christopher J Darus, Carol Aghajanian, Aikou Okamoto, Xiaohua Wu, Rustem Safin, Fan Wu, Luciana Molinero, Vidya Maiya, Victor K Khor, Yvonne G Lin, and Sandro Pignata
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells., Tamson V Moore, Gina M Scurti, Matthew DeJong, Siao-Yi Wang, Annika V Dalheim, Courtney R Wagner, Kelli A Hutchens, Jodi J Speiser, Constantine V Godellas, Chris Fountain, Jessica Fleser, Tarsem Moudgil, Mallory Thomas, David Murray, Brendan D Curti, Joseph I Clark, Bernard A Fox, and Michael I Nishimura
85 Detection of human angiotensin-converting enzyme 2 receptor (hACE2R) on human cancer cell lines, Tarsem Moudgil, Bernard A Fox, and Hong-Ming Hu
Induction of ADAM10 by RT drives fibrosis, resistance, and EMT in pancreatic cancer., Adam C Mueller, Miles Piper, Andrew Goodspeed, Shiv Bhuvane, Jason S Williams, Shilpa Bhatia, Andy V Phan, Benjamin Van Court, Kathryn L Zolman, Brisa Peña, Ayman J Oweida, Sara Zakem, Cheryl Meguid, Michael W Knitz, Laurel Darragh, Thomas E Bickett, Jacob Gadwa, Luisa Mestroni, Matthew R G Taylor, Kimberly R Jordan, Peter Dempsey, M Scott Lucia, Martin D McCarter, Marco Del Chiaro, Wells A Messersmith, Richard D Schulick, Karyn A Goodman, Michael J. Gough, Casey S Greene, James C Costello, Antonio Galvao Neto, David Lagares, Kirk C Hansen, Adrie Van Bokhoven, and Sana D Karam
509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer, Aung Naing, Brendan Curti, and See full list of authors in comments
Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report, Jasmine Naru, John E Godwin, and See full list of authors in comments
1665 - QuPath versus InForm: Digital image analysis of multiplex immunofluorescence (mIF) tumor-infiltrating lymphocyte (TIL) outcomes in an immunotherapy clinical trial, Benjamin Nikitin, Brie Chun, Isaac Kim, William L. Redmond, Katherine Sanchez, Zhaoyu Sun, Yaping Wu, and David B Page
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial., Makoto Nishio, Fabrice Barlesi, Howard West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome Goldschmidt, Silvia Novello, Francisco Orlandi, Rachel E Sanborn, Zsuzsanna Szalai, Grigoriy Ursol, Diana Mendus, Lijia Wang, Xiaohui Wen, Mark McCleland, Tien Hoang, See Phan, and Mark A Socinski
Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study, Yishai Ofran, John E Godwin, and See full list of authors in comments
Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia., Megan Othus, Guillermo Garcia-Manero, John E Godwin, James Weick, Derek Stirewalt, Frederick Appelbaum, Harry Erba, and Elihu Estey
Teaming up to Finish Triple-Negative Breast Cancer, David B Page
399 A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer, David B Page, Krystle Collins, Brie Chun, Zhaoyu Sun, Yoshinobu Koguchi, William L. Redmond, Maritza Martel, Yaping Wu, Nikki Moxon, Staci Mellinger, Walter Urba, Ayca Gucalp, and Tiffany Traina
A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer, David B Page, Krystle Collins, Brie Chun, Zhaoyu Sun, Yoshinobu Koguchi, William D Ryan, Maritza Martel, Yaping Wu, Nikki Moxon, Staci Mellinger, Walter Urba, Ayca Gucalp, and Tiffany A. Traina
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study., Keunchil Park, Eric B Haura, Natasha B Leighl, Paul Mitchell, Catherine A Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee, Joshua K Sabari, Alexander I Spira, Tsung-Ying Yang, Dong-Wan Kim, Ki Hyeong Lee, Rachel E Sanborn, José Trigo, Koichi Goto, Jong-Seok Lee, James Chih-Hsin Yang, Ramaswamy Govindan, Joshua M Bauml, Pilar Garrido, Matthew G Krebs, Karen L Reckamp, John Xie, Joshua C Curtin, Nahor Haddish-Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E Knoblauch, and Byoung Chul Cho
1247P - Management of infusion-related reactions (IRRs) in patients receiving amivantamab, K Park, JK Sabari, EB Haura, CA Shu, A Spira, R Salgia, KL Reckamp, Rachel E Sanborn, R Govindan, JM Bauml, JC Curtin, J Xie, A Roshak, P Lorenzini, D Millington, M Thayu, RE Knoblauch, and BC Cho
TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p., Girijesh Kumar Patel, Sayanika Dutta, Mosharaf Mahmud Syed, Sabarish Ramachandran, Monica Sharma, Venkatesh Rajamanickam, Vadivel Ganapathy, David J DeGraff, Kevin Pruitt, Manisha Tripathi, and Srinivas Nandana
A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress)., Amita Patnaik, Emiliano Calvo, Rachel E Sanborn, and See list of authors in comments
Integrated Personal Omics Profiling for Obesity, Brian D. Piening
Multi-Omics at Providence, Brian D. Piening
Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study., Evan P. Pisick, Matthew Rothe, Rom Leidner, and See list of authors in comments
961MO - Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers, MR Posner, AL Ho, J Niu, L Nabell, Rom Leidner, J Nieva, DL Richardson, AT Pearson, D Wang, K Chung, DR Adkins, A Pimentel, S Wong, C Iacobucci, X Qing, K Katchar, K Schlienger, I Matushansky, S Fu, and DG Pfister
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study., Christiane Querfeld, John A Thompson, Matthew H Taylor, Jennifer A DeSimone, Jasmine M Zain, Andrei R Shustov, Carolyn Johns, Sue McCann, Gloria H Y Lin, Penka S Petrova, Robert A Uger, Naomi Molloy, Yaping Shou, and Oleg E Akilov
Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens., Venkatesh Rajamanickam, Carmen Ballesteros-Merino, Kimberly Samson, David Ross, Brady Bernard, Bernard A Fox, Pippa Newell, Thomas Duhen, and Eric Tran
1360TiP First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study, SS Ramalingam, G de Castro Jr, MCC Garassino, J Mazieres, Rachel E Sanborn, EFF Smit, DR Spigel, M Thomas, V Velcheti, E Zhi, M Whipple Neibauer, A Stojadinovic, and S Peters
Efficient antigen cross-presentation through coating conventional aluminum adjuvant particles with PEI., Hongyan Ren, Yongbin Mou, Lin Lin, Lixin Wang, and Hongming Hu
558TiP - Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies, V Ribrag, D Davar, E Garralda, G Curigliano, J Zain, A Mehta, A Minchom, Rachel E Sanborn, F Foss, HK Oberoi, A Forero-Torres, and S Ansell
596 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity, Annah S Rolig, Daniel Rose, Grace Helen McGee, Saul Kivimae, Werner Rubas, and William L. Redmond
Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer, JK Sabari, CA Shu, K Park, N Leighl, P Mitchell, S Kim, J Lee, D Kim, S Viteri, A Spira, J Han, J Trigo, CK Lee, KH Lee, N Girard, T Yang, K Goto, Rachel E Sanborn, JC Yang, J Xie, A Roshak, M Thayu, RE Knoblauch, and BC Cho
601 Sequencing immunotherapy before lymphatic ablation unleashes cDC1-dependent antitumor immunity in HNSCC, Robert Saddami-Konefka, Shawn M. Jensen, Bernard A Fox, and See all authors in comments
Physical Activity Patterns and Relationships With Cognitive Function in Patients With Breast Cancer Before, During, and After Chemotherapy in a Prospective, Nationwide Study., Elizabeth A Salerno, Eva Culakova, Amber S Kleckner, Charles E Heckler, Po-Ju Lin, Charles E Matthews, Alison Conlin, Lora Weiselberg, Jerry Mitchell, Karen M Mustian, and Michelle C Janelsins
RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC, A Saltos, C Baik, Rachel E Sanborn, E Shum, C Kim, R Hall, MJ Fidler, CA Shu, G Otterson, J Patel, K Wong, N Hanna, J Gray, J Heymach, and X Le
Immunotherapy Combos: LAG-3, TIM-3, TIGIT, OX-40, Rachel E Sanborn
OncLive Data Review: ESMO Congress 2021, Rachel E Sanborn
A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies., Rachel E Sanborn, Rodolfo E. Bordoni, and See author list in comments
Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC, Rachel E Sanborn and Yousuf A. Gaffar
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study., Rachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, Patrick A Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A Autio, Daniel C Cho, Ruth Plummer, Mark Stroh, Lawrence Lu, and Fiona Thistlethwaite
398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC), Katherine Sanchez, Alison Conlin, Parvin Peddi, Sasha Stanton, Janet Ruzich, Kelly S Perlewitz, Yaping Wu, Nikki Moxon, Staci Mellinger, Zhaoyu Sun, William L. Redmond, and David B Page
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer., Katherine Sanchez, Isaac Kim, Brie Chun, Joanna Pucilowska, William L. Redmond, Walter Urba, Maritza Martel, Yaping Wu, Mary Campbell, Zhaoyu Sun, Gary Grunkemeier, Shu-Ching Chang, Brady Bernard, and David B Page
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma., Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, Karl D Lewis, Theresa Medina, Harriet M Kluger, Sajeve S Thomas, Evidio Domingo-Musibay, Anna C Pavlick, Eric D Whitman, Salvador Martin-Algarra, Pippa Corrie, Brendan D Curti, Judit Oláh, Jose Lutzky, Jeffrey S Weber, James M G Larkin, Wen Shi, Toshimi Takamura, Madan Jagasia, Harry Qin, Xiao Wu, Cecile Chartier, Friedrich Graf Finckenstein, Maria Fardis, John M Kirkwood, and Jason A Chesney
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer., Michael R Shafique, Terrence L Fisher, Elizabeth E Evans, John E Leonard, Desa Rae E Pastore, Crystal L Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M Chin, Joseph T Beck, Megan A Baumgart, Ramaswamy Govindan, Nashat Y Gabrail, Alexander I Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S Mansfield, Rachel E Sanborn, Jonathan W Goldman, and Maurice Zauderer
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection., Shay Sharon, Jason R Baird, Shelly Bambina, Gwen Kramer, Tiffany C Blair, Shawn M Jensen, Rom S Leidner, R Bryan Bell, Nardy Casap, Marka R Crittenden, and Michael J Gough
Explant Modeling of the Immune Environment of Head and Neck Cancer., Shay Sharon, Thomas Duhen, Shelly Bambina, Jason Baird, Rom Leidner, Bryan Bell, Nardy Casap, Marka Crittenden, Swetha Vasudevan, Maria Jubran, Nataly Kravchenko-Balasha, and Michael Gough
Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress)., Amna Falak Sher, Justine Yang Bruce, Nashat Y. Gabrail, Ian Churchill Anderson, Anna Patrikidou, Rachel E Sanborn, Jae Yong Cho, Arielle Shebay Lee, Jong-Seok Lee, Louise M. Nott, Do-Youn Oh, Sang Cheul Oh, Sung Yong Oh, Yinghui Wang, Zejing Wang, and Troy H. Guthrie
1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2, CA Shu, K Goto, Y Ohe, B Besse, K Park, Y Wang, F Griesinger, JC Yang, E Felip, Rachel E Sanborn, R Bernabe Caro, JM Bauml, J Chen, E Fennema, J Mahoney, L Trani, RE Knoblauch, M Thayu, and BC Chou
523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors, Elaine Shum, Rom Leidner, and See full list of authors in comments
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence., Craig L Slingluff, Karl D Lewis, Robert Andtbacka, John Hyngstrom, Mohammed Milhem, Svetomir N Markovic, Tawnya Bowles, Omid Hamid, Leonel Hernandez-Aya, Joel Claveau, Sekwon Jang, Prejesh Philips, Shernan G Holtan, Montaser F Shaheen, Brendan Curti, William Schmidt, Marcus O Butler, Juan Paramo, Jose Lutzky, Arvinda Padmanabhan, Sajeve Thomas, Daniel Milton, Andrew Pecora, Takami Sato, Eddy Hsueh, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Robert Weber, Edward Levine, Adam Berger, Anna Bar, J Thaddeus Beck, Jeffrey B Travers, Catalin Mihalcioiu, Brian Gastman, Peter Beitsch, Suthee Rapisuwon, John Glaspy, Edward C McCarron, Vinay Gupta, Deepti Behl, Brent Blumenstein, and Joanna J Peterkin
Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients., Sasha Stanton, Ekram Gad, Erik Ramos, Lauren Corulli, James Annis, Jennifer Childs, Hiroyuki Katayama, Samir Hanash, Jeffrey Marks, and Mary L Disis
1556 - Retinoid X receptor agonists enhances Th1 antigen-specific and polyfunctional T cells with the HER2-IGFBP2-IGF1R vaccine, Sasha Stanton, Erin Rodmaker, Nicholas Drovetto, Lauren Corulli, Flonia Levy, Venkatram Atigadda, Clinton Grubbs, Romaine Fernando, Shizuko Sei, and Mary L. Disis
Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG, Derek Stirewalt, John E Godwin, and See full list of authors in comments
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity., Elizabeth Sturgill, Annah S Rolig, Stefanie N Linch, Courtney Mick, Melissa Kasiewicz, Zhaoyu Sun, Peter G Traber, Harold Shlevin, and William L. Redmond
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study., Vivek Subbiah, Mimi I Hu, Lori J Wirth, Martin Schuler, Aaron S Mansfield, Giuseppe Curigliano, Marcia S Brose, Viola W Zhu, Sophie Leboulleux, Daniel W Bowles, Christina S Baik, Douglas Adkins, Bhumsuk Keam, Ignacio Matos, Elena Garralda, Justin F Gainor, Gilberto Lopes, Chia-Chi Lin, Yann Godbert, Debashis Sarker, Stephen G Miller, Corinne Clifford, Hui Zhang, Christopher D Turner, and Matthew H Taylor
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers., Zhaoyu Sun, Richard Nyberg, Yaping Wu, Brady Bernard, and William L. Redmond
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study., Matthew H Taylor, Courtney B Betts, Lauren Maloney, Eric Nadler, Alain Algazi, Michael J Guarino, John Nemunaitis, Antonio Jimeno, Priti Patel, Veerendra Munugalavadla, Lin Tao, Douglas Adkins, Jerome H Goldschmidt, Ezra E W Cohen, and Lisa M Coussens
Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer., Matthew H Taylor, Rom Leidner, Richard Bryan Bell, Bernard A Fox, and See full authors list in comments
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors., Matthew H Taylor, Emmett V Schmidt, Corina Dutcus, Elaine M Pinheiro, Yasuhiro Funahashi, Gregory Lubiniecki, and Drew Rasco
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib., Matthew H Taylor, Shunji Takahashi, Jaume Capdevila, Makoto Tahara, Sophie Leboulleux, Naomi Kiyota, Corina E Dutcus, Ran Xie, Bruce Robinson, Steven I Sherman, Mouhammed Amir Habra, Rossella Elisei, and Lori J Wirth
Intratumoral Plasmid IL12 Expands CD8, Melinda L Telli, Hiroshi Nagata, Irene Wapnir, Chaitanya R Acharya, Kaitlin Zablotsky, Bernard A Fox, Carlo Bifulco, Shawn M. Jensen, Carmen Ballesteros-Merino, Mai Hope Le, Robert H Pierce, Erica Browning, Reneta Hermiz, Lauren Svenson, Donna Bannavong, Kim Jaffe, Jendy Sell, Kellie Malloy Foerter, David A Canton, Christopher G Twitty, Takuya Osada, H Kim Lyerly, and Erika J Crosby
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study., Sara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, Alison Conlin, E Claire Dees, Shannon L Puhalla, Brent N Rexer, Howard A Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N Moore, Allison M Manuel, Andrew Lithio, Gregory L Price, Sonya C Chapman, Lacey M Litchfield, and Matthew P Goetz
583 Exploring the potential of T cell acute lymphoblastic leukemia (T-ALL) for generating leukemia-specific T cell responses that can be therapeutically harnessed with immunotherapy, Todd Triplett, Andrew D Weinberg, and See full list of authors in comments
Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT., Erica S Tsang, Gayle Funk, Janet Leung, Grace Kalish, and Hagen F Kennecke
Associations of Uncertainty With Psychological Health and Quality of Life in Older Adults With Advanced Cancer., Haydee C Verduzco-Aguirre, Dilip Babu, Supriya G Mohile, Javier Bautista, Huiwen Xu, Eva Culakova, Beverly Canin, Yingzi Zhang, Megan Wells, Ronald M Epstein, Paul Duberstein, Colin McHugh, William Dale, Alison Conlin, James Bearden, Jeffrey Berenberg, Mohamedtaki Tejani, and Kah Poh Loh
Enriching for Tumor-Reactive CD8 TIL with CD39/103 Markers: Implications for TIL Therapy, Andrew D. Weinberg
Adipocytes as Anticancer Drug Delivery Depot, D Wen, J Wang, and Z Gu
